AstraZeneca first-in-class ovarian cancer drug wins EU approval

December 18, 2014 7:46 AM

5 0

AstraZeneca first-in-class ovarian cancer drug wins EU approval

LONDON (Reuters) - AstraZeneca's all-important cancer drug business received a fillip on Thursday as a new medicine against ovarian cancer was approved in Europe, making it the first of its kind to reach the market.

AstraZeneca has flagged Lynparza, or olaparib, as a potential $2-billion-a-year seller.

Read more

To category page

Loading...